MYRIAD GENETICS, INC. Cost of Revenue
MYRIAD GENETICS, INC. (MYGN) reported Cost of Revenue of $63.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-31
- MYRIAD GENETICS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $63.70M, a 3.92% increase year-over-year.
- MYRIAD GENETICS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $62.80M, a 1.78% increase year-over-year.
- MYRIAD GENETICS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $63.00M, a 5.53% increase year-over-year.
- MYRIAD GENETICS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $61.90M, a 2.52% decline year-over-year.
- MYRIAD GENETICS, INC. cost of goods and services sold for fiscal 2025 was $247.90M, a 1.70% decline from fiscal 2024.
- MYRIAD GENETICS, INC. cost of goods and services sold for fiscal 2024 was $252.20M, a 6.77% increase from fiscal 2023.
- MYRIAD GENETICS, INC. cost of goods and services sold for fiscal 2023 was $236.20M, a 16.93% increase from fiscal 2022.
- MYRIAD GENETICS, INC. cost of goods and services sold for fiscal 2022 was $202.00M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $63.70M 10-Q · filed 2026-07-31 | $126.50M 10-Q · filed 2026-07-31 | $189.50M derived: sum of 3 quarters · filed 2026-07-31 | $251.40M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $62.80M 10-Q · filed 2026-05-06 | $125.80M derived: sum of 2 quarters · filed 2026-05-06 | $187.70M derived: sum of 3 quarters · filed 2026-05-06 | $249.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $63.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $124.90M derived: sum of 2 quarters · filed 2026-02-24 | $186.20M derived: sum of 3 quarters · filed 2026-07-31 | $247.90M 10-K · filed 2026-02-24 |
| 2025-09-30 | $61.90M 10-Q · filed 2025-11-04 | $123.20M derived: sum of 2 quarters · filed 2026-07-31 | $184.90M 10-Q · filed 2025-11-04 | $244.60M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $61.30M 10-Q · filed 2026-07-31 | $123.00M 10-Q · filed 2026-07-31 | $182.70M derived: sum of 3 quarters · filed 2026-07-31 | $246.20M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $61.70M 10-Q · filed 2026-05-06 | $121.40M derived: sum of 2 quarters · filed 2026-05-06 | $184.90M derived: sum of 3 quarters · filed 2026-05-06 | $249.30M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $59.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $123.20M derived: sum of 2 quarters · filed 2026-02-24 | $187.60M derived: sum of 3 quarters · filed 2026-02-24 | $252.20M 10-K · filed 2026-02-24 |
| 2024-09-30 | $63.50M 10-Q · filed 2025-11-04 | $127.90M derived: sum of 2 quarters · filed 2025-11-04 | $192.50M 10-Q · filed 2025-11-04 | $254.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $64.40M 10-Q · filed 2025-08-06 | $128.90M 10-Q · filed 2025-08-06 | $190.60M derived: sum of 3 quarters · filed 2026-02-24 | $248.20M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $64.60M 10-Q · filed 2025-05-07 | $126.20M derived: sum of 2 quarters · filed 2026-02-24 | $183.80M derived: sum of 3 quarters · filed 2026-02-24 | $241.60M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $61.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $119.20M derived: sum of 2 quarters · filed 2026-02-24 | $177.00M derived: sum of 3 quarters · filed 2026-02-24 | $236.20M 10-K · filed 2026-02-24 |
| 2023-09-30 | $57.60M 10-Q · filed 2024-11-08 | $115.40M derived: sum of 2 quarters · filed 2024-11-08 | $174.60M 10-Q · filed 2024-11-08 | $228.50M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $57.80M 10-Q · filed 2024-08-07 | $117.00M 10-Q · filed 2024-08-07 | $170.90M derived: sum of 3 quarters · filed 2025-02-28 | $221.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $59.20M 10-Q · filed 2024-05-08 | $113.10M derived: sum of 2 quarters · filed 2025-02-28 | $163.50M derived: sum of 3 quarters · filed 2025-02-28 | $213.20M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $53.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $104.30M derived: sum of 2 quarters · filed 2025-02-28 | $154.00M derived: sum of 3 quarters · filed 2025-02-28 | $202.00M 10-K · filed 2025-02-28 |
| 2022-09-30 | $50.40M 10-Q · filed 2023-11-07 | $100.10M derived: sum of 2 quarters · filed 2023-11-07 | $148.10M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $49.70M 10-Q · filed 2023-08-04 | $97.70M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $48.00M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |